Haematology and Leukaemia
Novartis Farma S.p.A. is active in clinical research focused on chronic myeloid leukaemia, with interest in disease control, molecular response, and long-term management of patients after treatment consolidation.
- Chronic myeloid leukaemia
- Major molecular response
- Treatment-free remission
The sponsor’s research activity in this area centres on maintaining deep disease response and evaluating sustained remission strategies in a haematological malignancy setting.
Remission Maintenance
Clinical interest extends to patients who remain in full treatment-free remission after consolidation, including those managed without ongoing therapy and those supported by reduced-dose treatment during remission monitoring.
- Full treatment-free remission
- Consolidation therapy
- Reduced-dose treatment
This area reflects a focus on preserving remission status over time and supporting durable disease control in chronic myeloid leukaemia.
Relapse Prevention and Re-treatment Planning
The sponsor also studies a second attempt at treatment-free remission, indicating interest in patients who require renewed remission strategies after prior treatment discontinuation.
- Second TFR attempt
- Molecular monitoring
- Remission re-establishment
These research themes are centred on sustaining major molecular response and understanding remission stability in later treatment pathways.
Oncology Clinical Research
Novartis Farma S.p.A.’s trial activity in oncology is specifically directed toward a blood cancer setting, with emphasis on long-term therapeutic management rather than broad multi-disease research.
- Blood cancer
- Long-term disease control
- Therapeutic discontinuation
The clinical landscape is concentrated in haematological oncology, with research sites based in Italy supporting this focused area of investigation.
